Drug Profile
Research programme: cancer vaccines - SELECT Therapeutics
Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator SELECT Therapeutics (CEASED)
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Nov 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 10 Aug 2000 New profile